Literature DB >> 33682527

Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial.

Sally Bendiks1, Debbie M Cheng2, Elena Blokhina3, Marina Vetrova3, Elena Verbitskaya3, Natalia Gnatienko1, Kendall Bryant4, Evgeny Krupitsky3,5, Jeffrey H Samet1,6, Judith I Tsui7.   

Abstract

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03278886.

Entities:  

Keywords:  HIV; Pain; alcohol; nalmefene; naltrexone

Year:  2021        PMID： 33682527      PMCID： PMC8421451          DOI： 10.1080/09540121.2021.1896663

Source DB:  PubMed          Journal:  AIDS Care        ISSN： 0954-0121


  40 in total

1.  Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals.

Authors:  Luke Hansen; Joanne Penko; David Guzman; David R Bangsberg; Christine Miaskowski; Margot B Kushel
Journal:  J Pain Symptom Manage       Date:  2011-07-30       Impact factor: 3.612

2.  Self-reported symptoms among HIV-lnfected patients on highly active antiretroviral therapy in the ATHENA cohort in The Netherlands.

Authors:  I Marion de Boer; Jan M Prins; Mirjam A G Sprangers; Colette Smit; Pythia T Nieuwkerk
Journal:  HIV Clin Trials       Date:  2011 May-Jun

3.  A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy.

Authors:  R C Chang; C Rota; R E Glover; R P Mason; J S Hong
Journal:  Brain Res       Date:  2000-01-31       Impact factor: 3.252

4.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).

Authors:  M A Chesney; J R Ickovics; D B Chambers; A L Gifford; J Neidig; B Zwickl; A W Wu
Journal:  AIDS Care       Date:  2000-06

5.  Pain as a global public health priority.

Authors:  Daniel S Goldberg; Summer J McGee
Journal:  BMC Public Health       Date:  2011-10-06       Impact factor: 3.295

6.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

7.  A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice.

Authors:  Shu-Lin Liu; Yi-Heng Li; Guey-Yueh Shi; Yung-Huan Chen; Chia-Wei Huang; Jau-Shyong Hong; Hua-Lin Wu
Journal:  J Am Coll Cardiol       Date:  2006-10-17       Impact factor: 24.094

8.  The global burden of low back pain: estimates from the Global Burden of Disease 2010 study.

Authors:  Damian Hoy; Lyn March; Peter Brooks; Fiona Blyth; Anthony Woolf; Christopher Bain; Gail Williams; Emma Smith; Theo Vos; Jan Barendregt; Chris Murray; Roy Burstein; Rachelle Buchbinder
Journal:  Ann Rheum Dis       Date:  2014-03-24       Impact factor: 19.103

9.  Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease.

Authors:  Mark J Atkinson; Anusha Sinha; Steven L Hass; Shoshana S Colman; Ritesh N Kumar; Meryl Brod; Clayton R Rowland
Journal:  Health Qual Life Outcomes       Date:  2004-02-26       Impact factor: 3.186

Review 10.  Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials.

Authors:  Karina Glies Vincents Johansen; Simon Tarp; Arne Astrup; Hans Lund; Anne K Pagsberg; Robin Christensen
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.